• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.06% Nasdaq Up0.22%

    Biogen Inc. (BIIB)

    -NasdaqGS
    318.46 Up 5.12(1.63%) 12:43PM EDT - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Biogen Inc.
    225 Binney Street
    Cambridge, MA 02142
    United States - Map
    Phone: 617-679-2000
    Website: http://www.biogenidec.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:7,550

    Business Summary 

    Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company’s products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS – SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer’s disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS – DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company was formerly known as Biogen Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Biogen Inc.

    Corporate Governance 
    Biogen Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 3. The pillar scores are Audit: 2; Board: 1; Shareholder Rights: 3; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. George A. Scangos Ph.D., 67
    Chief Exec. Officer and Director
    6.42M0.00
    Mr. Paul J. Clancy M.B.A., 53
    Chief Financial Officer and Exec. VP of Fin.
    1.84M0.00
    Ms. Adriana Karaboutis M.S., 52
    Exec. VP of Technology and Bus. Solutions
    2.48M0.00
    Dr. Alfred W. Sandrock Jr., M.D., Ph.D., 57
    Chief Medical Officer and Group Sr. VP
    1.32M0.00
    Dr. Adam M. Koppel M.B.A., M.D., Ph.D., 45
    Chief Strategy Officer and Sr. VP
    2.60M0.00
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders